Belite Bio Rolling NDA for Tinlarebant in Stargardt Disease
Key Questions
What is tinlarebant and what condition is it targeting?
Tinlarebant is an oral RBP4 inhibitor developed by Belite Bio for Stargardt Disease type 1. It modulates bisretinoid buildup in the retina, a key factor in the disease.
What supports Belite Bio's rolling NDA submission for tinlarebant?
The rolling New Drug Application (NDA) is supported by data from the phase 3 DRAGON trial in adolescents. It has received Breakthrough Therapy and Fast Track designations.
How does tinlarebant differ from other IRD treatments?
Tinlarebant represents the first small-molecule therapy for inherited retinal diseases (IRDs). It also has ties to a geographic atrophy (GA) trial potentially relevant to dry AMD.
Initiates rolling NDA for oral RBP4 inhibitor tinlarebant post-Ph3 DRAGON in adolescents (bisretinoid buildup mod); Breakthrough/FT designations, GA trial ties to dry AMD; first small-molecule shift in IRDs.
Sources (2)
Updated Apr 28, 2026